创新药将重塑本土仿创龙头药企估值: 从三生制药与辉瑞60.5亿美金deal说开去

Jo的随笔
20 May

近来,中国本土仿创结合龙头药企正经历一场深刻的变革,这场变革不仅体现在产品和业务结构的转型,更体现在市场对其价值的认知与重估。尤其是那些在仿制药领域有着深厚积累,同时积极布局创新药研发的仿创结合型药企,它们正在通过创新药管线的厚积薄发,逐步重塑自身的估值体系。2025年5月20日,三生制药与辉瑞近期达成60.5亿美金里程碑付款PD-1/VEGF双抗SSGJ-707授权协议,不仅是这家企业国际化进程...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10